戻る
Black Diamond Therapeutics Inc (BDTX)価格
BDTX 株価推移チャート
BDTX 財務
Black Diamond Therapeutics Inc
$2.22
1.36%
$0.03
終値： Feb 13, 16:00:00 GMT-5
$2.3
3.6%
$0.07
アフターマーケット：Feb 13, 20:00:00 GMT-5
収入
貸借対照表
現金の流れ
年次
四半期
BDTX 収入
金額は百万米ドル単位。会計年度は2月から1月まで。
Follow-Up Questions
Black Diamond Therapeutics Incの主要な財務諸表は何ですか？
BDTXの主要な財務比率は何ですか？
Black Diamond Therapeutics Incの収益はセグメントまたは地域別にどのように分けられていますか？
Black Diamond Therapeutics Incは収益を上げていますか？
Black Diamond Therapeutics Incに負債はありますか？
Black Diamond Therapeutics Incの発行済株式数は何株ですか？
主要データ
前終値
$2.19
始値
$2.2
当日レンジ
$2.2 - $2.3
52週レンジ
$1.19 - $4.94
取引高
476.1K
平均取引高
1.1M
1株当たり利益(TTM)
0.36
配当利回り
--
時価総額
$131.0M
BDTXとは何ですか？
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.